Summary
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Conditions
This trial is treating people with people who have received at least one gene-modified T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored trial, who have completed the post-treatment follow-up period in the parent trial